YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

SEHK:1558 Stock Report

Market Cap: HK$8.1b

YiChang HEC ChangJiang Pharmaceutical Past Earnings Performance

Past criteria checks 3/6

YiChang HEC ChangJiang Pharmaceutical's earnings have been declining at an average annual rate of -2.1%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 6% per year. YiChang HEC ChangJiang Pharmaceutical's return on equity is 17.5%, and it has net margins of 29.7%.

Key information

-2.1%

Earnings growth rate

-1.6%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate6.0%
Return on equity17.5%
Net Margin29.7%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Popularity With Investors Under Threat As Stock Sinks 26%

May 29
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Popularity With Investors Under Threat As Stock Sinks 26%

Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?

Apr 23
Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce

Mar 01
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce

Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%

Mar 01
Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't

Jan 03
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't

YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt

Sep 25
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt

Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?

Nov 25
Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?

Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?

Mar 23
Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?

Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?

Oct 29
Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?

Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden

Apr 13
Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially

Mar 23
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially

YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.

Mar 13
YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.

YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?

Feb 20
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?

Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?

Feb 02
Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Dec 26
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend

Dec 13
Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend

What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Nov 30
What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Revenue & Expenses Breakdown

How YiChang HEC ChangJiang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:1558 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 245,5401,6481,891360
31 Mar 245,9171,8201,915276
31 Dec 236,2951,9931,939192
30 Sep 235,9781,5661,870190
30 Jun 235,6611,1391,801187
31 Mar 234,7036081,676158
31 Dec 223,745771,551130
30 Sep 222,875-181,324115
30 Jun 222,005-1131,097101
31 Mar 221,459-351990105
31 Dec 21914-588883110
30 Sep 21690-43698698
30 Jun 21467-2851,08987
31 Mar 211,4072771,27890
31 Dec 202,3488391,46892
30 Sep 203,7921,2041,93374
30 Jun 205,2361,5682,39955
31 Mar 205,7301,7432,63427
31 Dec 196,2241,9192,8690
30 Sep 195,1621,5982,3560
30 Jun 194,0991,2761,8430
31 Mar 193,3051,1091,4410
31 Dec 182,5109431,0380
30 Sep 182,4669619680
30 Jun 182,4229808970
31 Mar 182,0128137310
31 Dec 171,6026475650
30 Sep 171,3255574430
30 Jun 171,0484673220
31 Mar 179954243180
31 Dec 169423813140
30 Sep 169043542940
30 Jun 168663272740
31 Mar 167792972360
31 Dec 156932661970
30 Sep 156372361900
30 Jun 155812071830
31 Mar 155111711770
31 Dec 144411351700
31 Dec 13316581410

Quality Earnings: 1558 has a large one-off loss of CN¥481.5M impacting its last 12 months of financial results to 30th June, 2024.

Growing Profit Margin: 1558's current net profit margins (29.7%) are higher than last year (20.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 1558's earnings have declined by 2.1% per year over the past 5 years.

Accelerating Growth: 1558's earnings growth over the past year (44.7%) exceeds its 5-year average (-2.1% per year).

Earnings vs Industry: 1558 earnings growth over the past year (44.7%) exceeded the Pharmaceuticals industry 2.9%.


Return on Equity

High ROE: 1558's Return on Equity (17.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies